Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986525 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A: BMS-986525 Monotherapy Dose Escalation | EXPERIMENTAL | - |
| Part 2A: BMS-986525 Monotherapy Dose Expansion | EXPERIMENTAL | - |
| Part 1B: BMS-986525 Combination with Pumitamig Dose Escalation | EXPERIMENTAL | - |
| Part 2B: BMS-986525 Combination with Pumitamig Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986525 | DRUG | Specified dose on specified days |
| Pumitamig | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC). * Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines. * In count...
Top 20 of 90 competitors
BMS-986525 is an investigational small molecule being developed for the treatment of relapsed/refractory small cell lung cancer. It is currently in Phase 1 clinical development, meaning it has not been approved by regulatory authorities and is still being studied for safety and tolerability.
BMS-986525 is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in patients with relapsed/refractory small cell lung cancer.
BMS-986525 is in Phase 1 clinical development. It is an investigational drug, not yet approved by the FDA or other regulatory bodies. The ongoing Phase 1 trial is recruiting participants to assess the safety and tolerability of the drug, both alone and in combination therapy.
BMS-986525 is being studied in a Phase 1 clinical trial with the identifier NCT07325136. This trial is currently recruiting and aims to enroll 240 participants with relapsed/refractory small cell lung cancer. The study is being conducted in the United States, China, Italy, Japan, Romania, and Spain.
No alternative names for BMS-986525 have been reported. The drug is identified solely by its development code BMS-986525 and is being studied under the clinical trial NCT07325136 for relapsed/refractory small cell lung cancer.